<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417014</url>
  </required_header>
  <id_info>
    <org_study_id>CCLG-HD-8201</org_study_id>
    <secondary_id>CDR0000454559</secondary_id>
    <secondary_id>EU-20585</secondary_id>
    <nct_id>NCT00417014</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma</brief_title>
  <official_title>Hodgkins Disease Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as chlorambucil, vinblastine, procarbazine, and&#xD;
      prednisolone, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to&#xD;
      kill cancer cells. Giving more than one drug (combination chemotherapy) together with&#xD;
      radiation therapy may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving combination chemotherapy and/or&#xD;
      radiation therapy works in treating young patients with Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Establish a uniform practice for the management of children with Hodgkin's lymphoma.&#xD;
&#xD;
        -  Document the long-term side effects of such management.&#xD;
&#xD;
        -  Establish whether or not children can be safely managed without staging laparotomy and&#xD;
           splenectomy.&#xD;
&#xD;
        -  Establish whether or not chlorambucil, vinblastine, procarbazine hydrochloride, and&#xD;
           prednisolone (CLVPP) is an effective alternative to mechlorethamine, vincristine,&#xD;
           procarbazine hydrochloride, and prednisone (MOPP) chemotherapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 3 treatment regimens&#xD;
      according to disease stage and presence of bulky mediastinal disease.&#xD;
&#xD;
        -  Involved-field radiotherapy (for patients with stage IA [nodal] disease): Patients&#xD;
           undergo involved-field radiotherapy 5 days a week for 4 weeks.&#xD;
&#xD;
        -  CLVPP chemotherapy (for patients with all other stages of disease AND no bulky&#xD;
           mediastinal disease): Patients receive CLVPP chemotherapy comprising oral chlorambucil,&#xD;
           oral procarbazine hydrochloride, and oral prednisolone on days 1-14 and vinblastine IV&#xD;
           on days 1 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  CLVPP chemotherapy and radiotherapy (for patients with all other stages of disease AND&#xD;
           bulky mediastinal disease): Patients receive CLVPP chemotherapy as above. Patients then&#xD;
           undergo radiotherapy to the mediastinum beginning 2 weeks after completing the last&#xD;
           course of CLVPP chemotherapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 358 patients were accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">358</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorambucil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy proven Hodgkin's lymphoma&#xD;
&#xD;
               -  Any stage allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Martin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Liverpool Children's Hospital, Alder Hey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Barratt, MD</last_name>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Chlorambucil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

